Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma's progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of Angelini's USD 960 million Arvelle acquisition, why he is optimistic about success in the challenging brain health space, and how the company's collaborative partnership strategy sets it apart from its rivals.
Brain health is not easy science because of the lack of biomarkers. However, with the right team, which I am convinced we have, a company of our size can successfully compete, growing sustainably over time
